| dc.contributor.author | Zghoul, Tarek | |
| dc.date.accessioned | 2021-03-31T17:03:12Z | |
| dc.date.available | 2021-03-31T17:03:12Z | |
| dc.date.issued | 2020-06 | |
| dc.identifier.citation | Zghoul, T. (2020). Can we prevent seasonal affective disorder (SAD) with melatonergic agents? BJPsych Advances, 26(4), 193-197. | en |
| dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/764 | |
| dc.description | The article attached to this record is the Author(s) pre-/post- print version only. NOTE: this is not the version published in BJPsych Advances. Minor changes may have been made for publication.
Eligible users can access the full text via NHS OpenAthens (login required) | |
| dc.description.abstract | Seasonal affective disorder (SAD) is a recurrent form of major depression, particularly occurring in the winter months with a generally spontaneous remission in spring/summer. The predictable nature of this condition provides a potentially unique opportunity to prevent recurrence in sufferers of SAD. The Cochrane Review discussed here examines the evidence for melatonin and agomelatine in preventing SAD, putting its findings into their clinical context. | en |
| dc.description.uri | https://doi.org/10.1192/bja.2020.25 | en |
| dc.language.iso | en | en |
| dc.subject | Seasonal Affective Disorder (SAD) | en |
| dc.title | Can we prevent seasonal affective disorder (SAD) with melatonergic agents? | en |
| dc.type | Preprint | en |
| dc.contributor.discipline | Medical Trainee | en |